Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-10-24-Speech-3-182"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20071024.36.3-182"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
". −
The costs associated with introducing ‘intellectual property’ protection standards in the pharmaceutical sector in ‘developing countries’ have been known about for a long time.
The dramatic and unacceptable situation caused in these countries by the application of ‘intellectual property rights’ in the area of health, particularly in the fight against diseases such as malaria, HIV/AIDS and tuberculosis, has been highlighted and warned about for a long time.
We therefore feel that this report represents an opportunity lost by the majority of this House, within the scope of its powers, to assume a humanist position and to clearly fight for a policy which could bring an end to intellectual property rights in the pharmaceutical sector.
Hiding behind the idea that a negotiation of the Protocol seems very difficult, the majority of this House have signed a blank cheque to the Council because such vague recommendations can only cause the current situation to continue, creating financial and legal obstacles which will prevent those countries with fewer resources from being able to access the advances made in science and technology in this field.
We abhor the fact that it is particularly the pharmaceutical multinationals that will gain through this inhumane policy, by maintaining their fabulous profits at the cost of many lives."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples